IPP Bureau

Evertis selects Honeywell Aclar technology to enhance pharmaceutical packaging
Evertis selects Honeywell Aclar technology to enhance pharmaceutical packaging

By IPP Bureau - June 11, 2025

Honeywell Aclar film technology will enable Evertis to develop high-quality barrier packaging solutions

Brenntag Specialties acquires mcePharma to cater growing demand in Biopharma market
Brenntag Specialties acquires mcePharma to cater growing demand in Biopharma market

By IPP Bureau - June 11, 2025

The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market

Cadila launches beta-blocker Biscado for treatment of cardiovascular diseases
Cadila launches beta-blocker Biscado for treatment of cardiovascular diseases

By IPP Bureau - June 10, 2025

Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,

Glenmark Pharmaceuticals to launch DCGI-approved BRUKINSA in India for treatment of hematological malignancies
Glenmark Pharmaceuticals to launch DCGI-approved BRUKINSA in India for treatment of hematological malignancies

By IPP Bureau - June 10, 2025

Globally, BRUKINSA is approved in more than 70 countries

Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites
Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites

By IPP Bureau - June 09, 2025

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021

Lupin receives tentative approval from USFDA for Oxcarbazepine ER Tablets
Lupin receives tentative approval from USFDA for Oxcarbazepine ER Tablets

By IPP Bureau - June 09, 2025

Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)

Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

By IPP Bureau - June 09, 2025

46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options

Health Minister Nadda delivers keynote address at FSSAI’s World Food Safety Day 2025
Health Minister Nadda delivers keynote address at FSSAI’s World Food Safety Day 2025

By IPP Bureau - June 09, 2025

Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme

Fujifilm rebrands life sciences companies to strengthen position as strategic partners for life
Fujifilm rebrands life sciences companies to strengthen position as strategic partners for life

By IPP Bureau - June 07, 2025

Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life

DuPont adds sterile packaging capacity of healthcare manufacturing site in Costa Rica
DuPont adds sterile packaging capacity of healthcare manufacturing site in Costa Rica

By IPP Bureau - June 07, 2025

The 16,000-square-foot expansion enhances DuPont’s global sterile operations

AstraZeneca’s fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia
AstraZeneca’s fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia

By IPP Bureau - June 07, 2025

AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations

Linerixibat new drug application accepted for review by the USFDA for cholestatic pruritus in patients with PBC
Linerixibat new drug application accepted for review by the USFDA for cholestatic pruritus in patients with PBC

By IPP Bureau - June 07, 2025

If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference

NPPA fixes retail prices for 41 drug combinations
NPPA fixes retail prices for 41 drug combinations

By IPP Bureau - June 06, 2025

The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments

New Reverse Osmosis pure water dialysis system unveiled by NIPRO at ERA 2025
New Reverse Osmosis pure water dialysis system unveiled by NIPRO at ERA 2025

By IPP Bureau - June 06, 2025

Thyrocare opens diagnostic lab in Srinagar
Thyrocare opens diagnostic lab in Srinagar

By IPP Bureau - June 06, 2025

33rd lab in Thyrocare’s expanding network to bring advanced, affordable diagnostic services across the Kashmir Valley

Latest Stories

Interviews

Packaging